B-3 500MG CONTINUOUS RELEASED 500 MG — DIN 00534978
NICOTINIC ACID : 500 MG · GAHLER ENTERPRISES LTD. · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is B-3 500MG CONTINUOUS RELEASED?
B-3 500MG CONTINUOUS RELEASED 500 MG contains NICOTINIC ACID : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 00534978, held by GAHLER ENTERPRISES LTD., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 01-Aug-2000. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Nicotinic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
25 holders have a Canadian DIN containing Nicotinic Acid, across 36 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GREAT EARTH COMPANIES, INC. | 4 | 0 | NIACIN 100MG, NIACIN 250MG, NIACIN 500MG, NIACIN 50MG | No marketed DIN |
| ANABOLIC LABORATORIES INC. | 2 | 0 | NIACIN SRC 400MG, TRI B3 SRC 300MG | No marketed DIN |
| GAHLER ENTERPRISES LTD. | 2 | 0 | B-3 500MG CONTINUOUS RELEASED, NIACIN 100MG TAB | No marketed DIN |
| KRIPPS PHARMACY LTD. | 2 | 0 | NIACIN INJ 100MG/ML, NIACIN PWR 800MG/1.25ML | No marketed DIN |
| KSL PHARMACEUTICALS | 2 | 0 | NIACIN TABLETS 500MG USP, SUSTAINED RELEASE NIACIN 500MG | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | NIACIN TAB 50MG, NIACIN-100 TAB 100MG | No marketed DIN |
| QUEST VITAMINS A DIV OF PURITY LIFE HEALTH PRODUCTS | 2 | 0 | NIACIN CAP 250MG, NIACIN TAB 500MG | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 2 | 0 | NIACIN TAB 100MG, NIACIN TAB 500MG | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 2 | 0 | NIACIN 100MG, NIACIN 500MG | No marketed DIN |
| BIOENERGY INC. | 1 | 0 | NIACIN CTR SRT 500MG | No marketed DIN |
| GENERAL NUTRITION CANADA INC. | 1 | 0 | NIACIN 100 MG TABLETS | No marketed DIN |
| GOLDEN PRIDE/RAWLEIGH | 1 | 0 | FORMULA # 7 TAB 50MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nicotinic Acid |
|---|---|
| ATC code | C04AC01 |
| AHFS class | 88:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00534978 |
|---|---|
| DIN (unpadded, as printed on some documents) | 534978 |
| Brand name | B-3 500MG CONTINUOUS RELEASED |
| Generic / active ingredient | NICOTINIC ACID : 500 MG |
| Market authorization holder | GAHLER ENTERPRISES LTD. |
| Health Canada schedule | Prescription |
| ATC code | C04AC01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C04AC |
| Current status | CANCELLED POST MARKET |
| Status date | 01-Aug-2000 |
| Original market date | 1981-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACTI-NIACIN CAPLET 500MG | 500 MG | TABLET | ACTI-FORM LTD. | CANCELLED POST MARKET | 01900668 |
| FORMULA # 7 TAB 50MG | 50 MG | TABLET | GOLDEN PRIDE/RAWLEIGH | CANCELLED POST MARKET | 02047276 |
| NIACIN 100 MG | 100 MG | CAPSULE | FLORA MANUFACTURING AND DISTRIBUTING LTD. | CANCELLED POST MARKET | 02244904 |
| NIACIN 100 MG TABLETS | 100 MG | TABLET | GENERAL NUTRITION CANADA INC. | CANCELLED POST MARKET | 02164140 |
| NIACIN 100MG | 100 MG | TABLET | GREAT EARTH COMPANIES, INC. | CANCELLED POST MARKET | 02230609 |
| NIACIN 100MG | 100 MG | TABLET | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | 00268585 |
| NIACIN 100MG TAB | 100 MG | TABLET | GAHLER ENTERPRISES LTD. | CANCELLED POST MARKET | 00619132 |
| NIACIN 100MG TABLETS USP | 100 MG | TABLET | PHARMETICS (2011) INC | CANCELLED POST MARKET | 02239694 |
| NIACIN 250MG | 250 MG | TABLET | GREAT EARTH COMPANIES, INC. | CANCELLED POST MARKET | 02230610 |
| NIACIN 500MG | 500 MG | TABLET | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | 00294950 |
2 · Same class — other molecules in ATC C04AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nicotinic Acid | ACTI-NIACIN CAPLET 500MG · B-3 500MG CONTINUOUS RELEASED · FORMULA # 7 TAB 50MG · NIACIN 100 MG · +27 more | 36 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C04AD | Pentoxifylline · Xantinol Nicotinate | 9 | 2 |
| C04AB | Phentolamine | 3 | 1 |
| C04AA | Buphenine | 3 | 0 |
| C04AE | Ergoloid Mesylates | 1 | 0 |
| C04AX | Cyclandelate | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.